Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Next Previous
Trial Profile

A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bio-Thera Solutions; Biothera

Most Recent Events

  • 07 Dec 2023 According to a Bio-Thera Solutions media release, United States Food and Drug Administration has approved Avzivi (bevacizumab-tnjn), a biosimilar referencing Avastin.
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 28 Jan 2021 According to a Bio-Thera Solutions media release, based on the data from this study and a few other studies, U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin (bevacizumab).The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is November 27, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top